≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
AZ084 is a potent, selective, allosteric and oral active CCR8 allosteric antagonist, with a K i of 0.9 nM. Has potential to treat asthma AZ084 restrains the formation of the immunologically tolerant pre-metastatic niche (PMN) and tumor cells metastasis in lung by downregulating Treg differentiation. AZ084 can be used in studies of asthma and cancer
In Vitro
AZ084 (5 μg/mL; single daily for 4 days) suppresses proportion of Tregs and reduces T cells that expresses CCR8 (co-cultured in vitro with LLC-exo MPF CM). ?\nAZ084 (0-10 μM) inhibits AML, DC and T cells with IC 50 s of 1.3, 4.6 and 5.7 nM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Splenic T cells Concentration: 5 μg/mL (single daily) Incubation Time: 4 days Result: Reversed the increased proportion of Tregs among the CD4+ T cells co-cultured in vitro with LLC-exo MPF CM. Reduced T cells that expressed CCR8 (cultured in vitro with by LLC-exo MPF CM). Cell Viability AssayCell Line: AML, DC and T cells Concentration: 0-10 µM Incubation Time: Result: Showed high potency with pronounced dose-response dependent inhibition of chemotaxis with an IC 50 of 1.3 nM in AML cells.
In Vivo
AZ084 (5 mg/kg; i.p.; every third day for 9 or 21 days) restrains the formation of the immunologically tolerant PMN and tumor cells metastasis in lung by downregulating Treg differentiation . ?\nAZ084 (434.57-869.14 mg/kg; i.v.; single) shows a bioavailability >70% in rats. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 J mice (subcutaneous LLC tumor model) . Dosage: 5 mg/kg Administration: Intraperitoneal injection, every third day for 9 or 21 days. Result: Inhibited Treg differentiation and tumor cell colonization of the lungs and reduced the number of CD4+Foxp3+ Tregs in the lungs of LLC-exo pre-injected mice (every third day for 9 days). Inhibited the LLC-exo-induced LLC cell seeding in lung and also significantly reduced Treg accumulation in LLC-exo stimulated mouse lungs(every third day for 21 days). Animal Model: Female Balb/C mice, male Wistar rats and female Beagle dogs. Dosage: 434.57-869.14 mg/kg (in 0.9% NaCl) Administration: Intravenous injection, single. Result: 1.19 Pharmacokinetic Parameters of AZ084 in Female Balb/C mice, male Wistar rats and female Beagle dogs. IV (434.57-869.14 mg/kg) Dog plasma protein binding (% free) 45.7 Mu plasma protein binding (% free) 55.6 Hu plasma protein binding (% free) 31.0 Rat plasma protein binding (% free) 47.0 Rat HW plasma PK CL (mL/min/kg) 15.0 Rat HW plasma PK V ss (L/kg) 6.0 Rat HW plasma PK T 1/2 (h) 5.4 Rat HW plasma PK C max (µM) 0.5 Rat HW plasma PK bioavailability (%) 68.0
Form:Solid
IC50& Target:CCR8 0.9 nM (Ki)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organoheterocyclic compounds |
| 분류 | Azaspirodecane derivatives |
| Subclass | Not available |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Azaspirodecane derivatives |
| Alternative Parents | Pyridinecarboxylic acids and derivatives N-acylpiperidines Coumarans 2-heteroaryl carboxamides Alkyl aryl ethers Aminopyridines and derivatives Aralkylamines Benzenoids Tertiary carboxylic acid amides Heteroaromatic compounds Amino acids and derivatives Trialkylamines Azacyclic compounds Oxacyclic compounds Organic oxides Primary amines Hydrocarbon derivatives |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | Azaspirodecane - Pyridine carboxylic acid or derivatives - N-acyl-piperidine - Coumaran - 2-heteroaryl carboxamide - Aralkylamine - Aminopyridine - Alkyl aryl ether - Pyridine - Piperidine - Benzenoid - Heteroaromatic compound - Tertiary carboxylic acid amide - Carboxamide group - Tertiary aliphatic amine - Tertiary amine - Amino acid or derivatives - Oxacycle - Carboxylic acid derivative - Ether - Azacycle - Organic oxygen compound - Amine - Organic nitrogen compound - Hydrocarbon derivative - Organic oxide - Organonitrogen compound - Organooxygen compound - Primary amine - Aromatic heteropolycyclic compound |
| 설명 | This compound belongs to the class of organic compounds known as azaspirodecane derivatives. These are organic compounds containing a spirodecane moiety with at least one nitrogen atom. |
| External Descriptors | Not available |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| 용해성 | DMSO : 250 mg/mL (575.28 mM; Need ultrasonic) |
|---|---|
| 분자량 | 434.600 g/mol |
| XLogP3 | 3.200 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 3 |
| Exact Mass | 434.268 Da |
| Monoisotopic Mass | 434.268 Da |
| Topological Polar Surface Area | 71.700 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 665.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |
